# Regulation of androgen receptor expression by enhancer elements in prostate cancer

## TL;DR

This paper explores how DNA regions called enhancers near the androgen receptor gene contribute to prostate cancer resistance to treatment.

## Contribution

The paper identifies enhancer elements as key regulators of androgen receptor overexpression in castration-resistant prostate cancer.

## Key findings

- Enhancer elements near the AR gene increase AR transcription through enhancer-promoter looping.
- Increased enhancer activity or copy number is linked to elevated AR expression and treatment resistance.
- Targeting these enhancers may provide new therapeutic strategies for resistant prostate cancer.

## Abstract

Androgen receptor (AR) overexpression is a key mechanism driving the development of castration-resistant prostate cancer (CRPC). This can result from multiple factors, including enhanced AR transcription and increased stability of AR mRNA and protein. In clinical CRPC samples, one cause of AR overexpression is gene amplification at the AR locus, which leads to elevated AR transcript and protein levels. In addition, increased activity or copy number of enhancer elements near the AR gene has been associated with elevated AR transcription. These regulatory regions interact with the AR gene promoter through enhancer–promoter looping, thereby enhancing AR mRNA transcription. Elucidating the role of these enhancer elements in driving AR overexpression and aberrant AR signaling may uncover new therapeutic targets for CRPC.

Prostate cancer is a major health issue for men worldwide, with advanced stages being particularly deadly. The review focuses on understanding why some prostate cancers become resistant to current treatments. Researchers explored how certain parts of the DNA near the androgen receptor (AR) gene contribute to this resistance. The studies used various techniques to examine prostate cancer cells and tissues. They identified specific DNA regions, called enhancers, that boost AR gene transcription. These enhancers can become more active or increase in number, leading to higher AR levels, which helps cancer resist treatment. Key findings show that these enhancers, when amplified or activated, significantly increase AR expression. This contributes to treatment resistance in advanced prostate cancer. The researchers suggest that targeting these enhancers could offer new ways to treat resistant prostate cancer.